The primary cause of mortality from prostate cancer is the progression to metastatic disease in patients with CRPC, but it is still unclear what transcriptional relationships are shared between responses to ADT and metastasis. Thus, we aimed to find concerted transcription factor relationships that characterize the differential transcriptional response of patients that received ADT, as well as the progression from localized prostate cancer to metastatic disease.
INTRODUCTION AND OBJECTIVES:
The primary cause of mortality from prostate cancer is the progression to metastatic disease in patients with CRPC, but it is still unclear what transcriptional relationships are shared between responses to ADT and metastasis. Thus, we aimed to find concerted transcription factor relationships that characterize the differential transcriptional response of patients that received ADT, as well as the progression from localized prostate cancer to metastatic disease.
METHODS: To investigate differential responses to ADT, We generated whole transcriptome gene expression data from 20 patientmatched formalin-fixed prostate needle core biopsies, taken before initiation of ADT, and corresponding formalin-fixed radical prostatectomy samples, acquired after ADT, and leveraged a large dataset (n > 1200) of multiple publicly available cohorts of primary and metastatic tumors, to reverse engineer transcriptional networks. We combined these analyses to uncover groups of putative transcription factor regulators that were unique to patients demonstrating a strong transcriptional response to ADT, as well as to patients with metastatic prostate cancer. Here we identify transcription factor coordinated groups (TFCGs), such as AR with CEBP factors, that are significantly associated with both a strong response to ADT, and metastatic lesions, as compared to primary tumors. Our analysis leverages multiple datatypes and independent datasets to find common TFCGs, that may serve as putative regulators of prostate cancer aggressiveness. We performed differential expression analysis of RNA-Seq data derived from 40 matched Bx and RPs from 20 patients obtained before and after ADT. We identified 190 significantly differentially expressed genes with a fold change greater than or equal to 2 (FDR < 0.05).
RESULTS: As expected, Ingenuity Pathway analysis (IPA) identified chemical agents related to AR-signaling and activation, such as dihydrotestosterone and the AR agonist metribilone (R1881) as being inhibited. Additionally, targets of U0126 (6 (1,4-diamino-2,3-dicyano-1,4 bis[2-aminophenylthio] butadiene), an inhibitor of MEK1 in the MAPK signaling pathway, were also downregulated by IPA analysis, suggesting MAPK activation. Additionally, beta-estradiol (estrogen) and PDGF were both predicted to be activated. Subtyping of the Post-ADT samples again revealed three groups, consistent with the clustering of significantly differentially expressed genes. Strikingly, we observed a subtype shift from the Pre-ADT Bxs that predominantly expressed PCS2 genes, to the PCS1 strong responders, or the PCS3 weak responders. Integrating the inherent biological characteristics of each subtype, these data suggest a possible ADT-induced selection from a PCS2 AR-dependent, ADT-sensitive tumor to either a more aggressive PCS1 or more benign PCS3 tumor. Furthermore, the observation that the strong responders exhibited expression of PCS1 genes implies that these samples may potentially become ADT resistant.
CONCLUSIONS: Our analysis utilizes a novel dataset that interrogates causal effects of ADT alone in matched samples, and integrates these data with a large cohort of primary and metastatic tumors to predict common mechanisms important to resistance to therapy and progression to metastatic disease. This hypothesis-driving study sheds light on important coordinated transcription factor activities that may serve as critical upstream regulators of prostate cancer aggressiveness, progression, metastasis, and development of androgen-resistance. Using this unbiased approach, we have identified transcriptional regulators associated with differential ADT responses and metastatic disease progression.
Multiparametric magnetic resonance imaging (MRI) is widely used to aid the diagnosis and treatment of prostate cancer. However, not all tumors are seen on MRI, including some high grade and potentially lethal tumors. We aim to better understand the molecular basis and prognostic implications for tumor visibility on MRI.
METHODS: Detailed maps of prostate cancers were created using radical prostatectomy specimens. Tumors visible and invisible on MRI were macrodissected and analyzed by RNA sequencing. Differentially expressed genes (DEGs) were cross-referenced with public databases to identify genes associated with disease progression, metastasis and MRI visibility. A multivariate analysis was performed using these genes along with standard clinical variables. One of these genes was knocked-down in a human prostate cancer cell line. This was used to generate xenograft tumors in mice that were imaged on MRI.
RESULTS: 1,654 DEGs were identified based on MRI visibility status. DEGs based on Gleason score and tumor size were also identified. Gleason score (dissimilarity test, p<0.0001) and tumor size (p<0.039) did not fully explain MRI visibility. Four genes (PHYDH1, CENPF, ALDH2, GDF15) predicted MRI visibility, were associated with metastasis, and predicted progression free survival. These fours genes (MRI4) did not correlate with tumor size (r¼-0.62 to 0.41) suggesting that MRI4 does not simply reflect tumor growth. Multivariate analysis showed that MRI4 was a significant predictor of recurrence free survival independent of PSA, stage, and grade (p¼0.021). A reciprocal analysis of genes in two previously published prognostic signatures also predicted MRI visibility in our dataset. A human prostate cancer cell line was engineered to express MicroRNA-101 in the presence of doxycycline, which negatively regulates CENPF. The resulting tumors injected in mice fed doxycycline had decreased tumor growth and visibility on MRI. Immunohistochemical analysis suggests that decreased MRI visibility in these mice was due to decreased cell density and proliferation.
CONCLUSIONS: MRI visibility suggests a more favorable prognosis in prostate cancer. We identified four prognostic genes associated with MRI visibility, progression free survival, and metastasis. In animal studies, genetic manipulation of CENPF resulted in altered MRI visibility.
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